Iptacopan · Regulatory label update

FDA supplemental approval: Fabhalta (Efficacy)

U.S. Food and Drug Administration · July 16, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA granted a supplemental approval for Fabhalta (iptacopan) on 16 July 2026 for an efficacy-based indication. This regulatory action confirms agency authorization but does not disclose the clinical trial results, endpoints, or comparative data that supported the approval.

What was studied

Regulatory label update.

Key findings

FDA supplemental approval issued 2026-07-16 for FABHALTA (iptacopan hydrochloride 200 mg oral capsule)

Safety

Study design, sample size, population, comparator, and adverse event profile are not disclosed in this approval notice.

Who this may help

This record confirms regulatory authorization of iptacopan for an efficacy-based claim but does not provide the underlying trial data needed to assess clinical benefit, efficacy magnitude, or appropriate use in clinical practice. Clinicians should consult the full prescribing information and supporting trial summaries for efficacy and safety details.

Plain-language summary

FDA supplemental approval for expanded indication or new efficacy claim; regulatory action without trial outcome data in this record.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-16

Active ingredient dose200 mg base

Clinical bottom line

Caveats

This record contains no clinical trial results, efficacy data, endpoints, effect sizes, or comparative outcomes.
The specific indication or disease for which the efficacy supplement was approved is not stated in this regulatory record.
Study design, sample size, population, comparator, and adverse event profile are not disclosed in this approval notice.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record does not contain clinical study design details.

Directness

insufficient

No efficacy data or clinical outcomes reported in this approval record.

Consistency

insufficient

Single regulatory action; no comparative or replication data provided.

Risk of bias

insufficient

Regulatory record does not disclose study methodology or bias assessment.

Sample adequacy

insufficient

No sample size or population data reported in this approval notice.

Source abstract

Drugs@FDA record for application NDA218276. This is a regulatory action record, not a clinical study. Brand name: FABHALTA. Active ingredient: IPTACOPAN. Sponsor: NOVARTIS. Submission type: SUPPL (supplement). Submission class: Efficacy. Approval status date: 2026-07-16. Products: FABHALTA, CAPSULE, ORAL, IPTACOPAN HYDROCHLORIDE EQ 200MG BASE.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

IptacopanNovartis